Fisher Asset Management LLC Buys 5,777 Shares of United Therapeutics Corporation $UTHR

Fisher Asset Management LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 24.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,357 shares of the biotechnology company’s stock after acquiring an additional 5,777 shares during the period. Fisher Asset Management LLC owned 0.07% of United Therapeutics worth $14,304,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Sectoral Asset Management Inc. boosted its holdings in shares of United Therapeutics by 125.2% during the 4th quarter. Sectoral Asset Management Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $840,000 after buying an additional 958 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in shares of United Therapeutics by 303.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,131 shares of the biotechnology company’s stock valued at $551,000 after buying an additional 851 shares in the last quarter. Genus Capital Management Inc. bought a new stake in shares of United Therapeutics during the 4th quarter valued at $2,163,000. Hantz Financial Services Inc. boosted its holdings in shares of United Therapeutics by 66.8% during the 4th quarter. Hantz Financial Services Inc. now owns 1,570 shares of the biotechnology company’s stock valued at $765,000 after buying an additional 629 shares in the last quarter. Finally, Simplify Asset Management Inc. boosted its holdings in shares of United Therapeutics by 19.7% during the 4th quarter. Simplify Asset Management Inc. now owns 23,839 shares of the biotechnology company’s stock valued at $11,616,000 after buying an additional 3,919 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 581,973 shares of company stock valued at $325,968,044. 8.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on UTHR shares. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $570.75 on Thursday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The business has a 50-day simple moving average of $565.54 and a two-hundred day simple moving average of $514.75. The firm has a market cap of $24.23 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 1.87 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the firm posted $6.63 EPS. United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, research analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.